Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.8262
+$0.0126 · +1.55%
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
Regular session
$0.8262
+$0.0126 · +1.55%
Regular session · ET · Market data may be delayed.
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
Day range
Current $0.8262
52-week range
Current $0.8262
Regular session · ET · Market data may be delayed.
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
Day range
Current $0.8262
52-week range
Current $0.8262
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 936K USD | — | — | — | — |
| Gross profit | −936K USD | — | — | — | — |
| Research and development | 26.59M USD | 69.64M USD | 89.42M USD | 68.03M USD | 24.81M USD |
| Selling, general, and administrative | 67.86M USD | 71.81M USD | 16.53M USD | 11.99M USD | 8.06M USD |
| Operating expenses | 94.45M USD | 141.45M USD | 105.96M USD | 80.02M USD | 32.87M USD |
| Interest income | 4.62M USD | 8.51M USD | 7.83M USD | 2.78M USD | 49K USD |
| Depreciation and amortization | 936K USD | 1.13M USD | 1.53M USD | 1.3M USD | 534K USD |
| Operating income | −95.39M USD | −141.45M USD | −105.96M USD | −80.02M USD | −32.87M USD |
| Net income | −90.97M USD | −24.34M USD | −97.22M USD | −76.25M USD | −32.39M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWC
Vanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
